Sugi Predict

Sugi Predict / Compounds / SCHEMBL7853979

SCHEMBL7853979

SCHEMBL7853979

CCOC(=O)/C(C#N)=C(\O)C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.47
▸ TSHR P16473 1/20 0.47
▸ ACHE P22303 9/20 0.42
▸ CES2 O00748 7/20 0.42
▸ CES1 P23141 7/20 0.42
▸ CYP2C9 P11712 1/20 0.41
▸ MAPT P10636 5/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ MDM2 Q00987 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7853980 1.00 ALDH1A1 (0.47) ALDH1A1TSHRACHECES2CES1
SCHEMBL2592388 0.98 ALDH1A1 (0.46) ALDH1A1TSHRACHECES2CES1
SCHEMBL2592394 0.98 ALDH1A1 (0.46) ALDH1A1TSHRACHECES2CES1
SCHEMBL4623907 0.86 ALDH1A1 (0.44) ALDH1A1TSHRACHECES2CES1
SCHEMBL4623904 0.86 ALDH1A1 (0.44) ALDH1A1TSHRACHECES2CES1
SCHEMBL13237290 0.84 ALDH1A1 (0.48) ALDH1A1TSHRCYP2C9MAPTKMT2A
SCHEMBL13237291 0.81 TSHR (0.45) TSHRCES2CES1KMT2AMEN1
SCHEMBL4625345 0.81 ALDH1A1 (0.46) ALDH1A1TSHRCYP2C9MAPTKMT2A
SCHEMBL4625344 0.81 ALDH1A1 (0.46) ALDH1A1TSHRCYP2C9MAPTKMT2A
SCHEMBL28384074 0.81 ALDH1A1 (0.46) ALDH1A1TSHRCYP2C9MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4147700-A1 N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE LQT Therapeutics Inc. (CA) 2023-03-15 — — EP disclosed
US-9718825-B2 N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals SANOFI (FR) 2017-08-01 — — US disclosed
EP-2970259-B1 N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2016-12-21 — — EP disclosed
US-20160024097-A1 N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2016-01-28 — — US disclosed
EP-2970259-A1 N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2016-01-20 — — EP disclosed
WO-2014140065-A1 N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2014-09-18 — — WO disclosed
US-7749669-B2 Electrophotographic toner and image forming method KONICA MINOLTA HOLDINGS, INC. (JP) 2010-07-06 — — US disclosed
US-7678520-B2 Method for producing electrophotographic toner and electrophotographic toner KONICA MINOLTA HOLDINGS, INC. (JP) 2010-03-16 — — US disclosed
US-7470495-B2 Electrophotographic toner and image forming method KONICA MINOLTA HOLDINGS, INC. (JP) 2008-12-30 — — US disclosed
US-7364841-B2 Comprising support having thereon light-insensitive organic silver salt grains, photosensitive silver halide grains, a reducing agent for silver ions and a binder; improved storage stability, image lasting quality; use in medical diagnosis and graphic arts KONICA MINOLTA & MEDICAL GRAPHIC, INC. (JP) 2008-04-29 — — US disclosed
US-7211373-B2 Photothermographic material FUJIFILM CORPORATION (JP) 2007-05-01 — — US disclosed
US-20070092819-A1 Method for producing electrophotographic toner and electrophotographic toner KONICA MINOLTA HOLDINGS, INC. (JP) 2007-04-26 — — US disclosed
US-7202019-B2 Photothermographic imaging material KONICA MINOLTA HOLDINGS, INC. (JP) 2007-04-10 — — US disclosed
US-7175978-B2 Silver salt photothermographic dry imaging material KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-02-13 — — US disclosed
US-20070003886-A1 SILVER SALT PHOTOTHERMOGRAPHIC DRY IMAGING MATERIAL KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-01-04 — — US disclosed
JP-2001058982-A ESTER DERIVATIVE OF 5-AMINOPYRAZOLE-4-CARBOXYLIC ACID AND ITS PRODUCTION MITSUI CHEMICALS INC 2001-03-06 — — JP disclosed
EP-0914628-B1 BLACK-AND-WHITE PHOTOTHERMOGRAPHIC AND THERMOGRAPHIC ELEMENTS CONTAINING SUBSTITUTED PROPENENITRILE COMPOUNDS AS ANTIFOGGANTS EASTMAN KODAK CO (US) 2000-08-16 — — EP disclosed
EP-0914628-A1 BLACK-AND-WHITE PHOTOTHERMOGRAPHIC AND THERMOGRAPHIC ELEMENTS CONTAINING SUBSTITUTED PROPENENITRILE COMPOUNDS AS ANTIFOGGANTS Imation Corp. (US) 1999-05-12 — — EP disclosed
WO-1998004958-A1 BLACK-AND-WHITE PHOTOTHERMOGRAPHIC AND THERMOGRAPHIC ELEMENTS CONTAINING SUBSTITUTED PROPENENITRILE COMPOUNDS AS ANTIFOGGANTS IMATION CORP. (US) 1998-02-05 — — WO disclosed
US-5686228-A Substituted propenitrile compounds as antifoggants for black-and-white photothermographic and thermographic elements IMATION CORP. (US) 1997-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024097-A1 N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS SGK1, SGK3, SGK2 ALDH1A1 3312/4885TSHR 1746/4885ACHE 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.